<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31342410</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1149</StartPage><EndPage>1166</EndPage><MedlinePgn>1149-1166</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-019-00765-w</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder in which the neuromuscular junction progressively degenerates, leading to movement difficulties, paralysis, and eventually death. ALS is currently being treated by only two FDA-approved drugs with modest efficacy in slowing disease progression. Often, the translation of preclinical findings to bedside terminates prematurely as the evaluation of potential therapeutic compounds focuses on a single study or a single animal model. To circumscribe these issues, we screened 3,765 novel small molecule derivatives of pimozide, a recently identified repurposed neuroleptic for ALS, in Caenorhabditis elegans, confirmed the hits in zebrafish and validated the most active compounds in mouse genetic models. Out of the 27 small molecules identified from the high-throughput screen in worms, 4 were found to recover locomotor defects in C. elegans and genetic zebrafish models of ALS. TRVA242 was identified as the most potent compound as it significantly improved efficiency in rescuing locomotor, motorneuron, and neuromuscular junction synaptic deficits in a C. elegans TDP-43 model and in multiple zebrafish genetic (TDP-43, SOD1, and C9ORF72) models of ALS. The actions of TRVA242 were also conserved in a mammalian model as it also stabilized neuromuscular junction deficits in a mouse SOD1 model of ALS. Compounds such as TRVA242 therefore represent new potential therapeutics for the treatment of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bose</LastName><ForeName>Poulomee</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de recherche du centre hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CRCHUM Tour Viger R09-482), 900 Rue Saint Denis, Montr&#xe9;al, Quebec, H2X 0A9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremblay</LastName><ForeName>Elsa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FRQS Group de recherche sur le system nerveux centrale, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maios</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre de recherche du centre hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CRCHUM Tour Viger R09-482), 900 Rue Saint Denis, Montr&#xe9;al, Quebec, H2X 0A9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narasimhan</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Zebrafish Centre for Advanced Drug Discovery and Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital and Department of Medicine and Physiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Gary A B</ForeName><Initials>GAB</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University and Montreal Neurological Institute, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Meijiang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de recherche du centre hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CRCHUM Tour Viger R09-482), 900 Rue Saint Denis, Montr&#xe9;al, Quebec, H2X 0A9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>J Alex</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de recherche du centre hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CRCHUM Tour Viger R09-482), 900 Rue Saint Denis, Montr&#xe9;al, Quebec, H2X 0A9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robitaille</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FRQS Group de recherche sur le system nerveux centrale, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Xiao Yan</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Zebrafish Centre for Advanced Drug Discovery and Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital and Department of Medicine and Physiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barden</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Treventis Corporation, 60 Leonard Avenue, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drapeau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Quebec, Canada. p.drapeau@umontreal.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de recherche du centre hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CRCHUM Tour Viger R09-482), 900 Rue Saint Denis, Montr&#xe9;al, Quebec, H2X 0A9, Canada. p.drapeau@umontreal.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>1HIZ4DL86F</RegistryNumber><NameOfSubstance UI="D010868">Pimozide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neurotherapeutics. 2021 Jul;18(3):2128</RefSource><PMID Version="1">34100189</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010868" MajorTopicYN="N">Pimozide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">C. elegans</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">Mice</Keyword><Keyword MajorTopicYN="N">Motorneuron</Keyword><Keyword MajorTopicYN="N">NMJ</Keyword><Keyword MajorTopicYN="N">SOD-1</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">Therapeutics</Keyword><Keyword MajorTopicYN="N">Zebrafish</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31342410</ArticleId><ArticleId IdType="pmc">PMC6985319</ArticleId><ArticleId IdType="doi">10.1007/s13311-019-00765-w</ArticleId><ArticleId IdType="pii">10.1007/s13311-019-00765-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7(11):603&#x2013;15. doi: 10.1038/nrneurol.2011.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. Amyotrophic lateral sclerosis--a model of corticofugal axonal spread. Nat Rev Neurol. 2013;9(12):708&#x2013;14. doi: 10.1038/nrneurol.2013.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.221</ArticleId><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232&#x2013;40. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney EB, de Winter F, Verhaagen J. ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front Neurosci. 2014;8:252. doi: 10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark JA, Southam KA, Blizzard CA, King AE, Dickson TC. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. J Chem Neuroanat. 2016;76(Pt A):35&#x2013;47. doi: 10.1016/j.jchemneu.2016.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2016.03.003</ArticleId><ArticleId IdType="pubmed">27038603</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbour D, Tremblay E, Martineau E, Julien JP, Robitaille R. Early and persistent abnormal decoding by glial cells at the neuromuscular junction in an ALS model. J Neurosci. 2015;35(2):688&#x2013;706. doi: 10.1523/JNEUROSCI.1379-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1379-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605374</ArticleId><ArticleId IdType="pubmed">25589763</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay E, Martineau E, Robitaille R. Opposite Synaptic Alterations at the Neuromuscular Junction in an ALS Mouse Model: When Motor Units Matter. J Neurosci. 2017;37(37):8901&#x2013;18. doi: 10.1523/JNEUROSCI.3090-16.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3090-16.2017</ArticleId><ArticleId IdType="pmc">PMC6596800</ArticleId><ArticleId IdType="pubmed">28821658</ArticleId></ArticleIdList></Reference><Reference><Citation>So E, Mitchell JC, Memmi C, Chennell G, Vizcay-Barrena G, Allison L, et al. Mitochondrial abnormalities and disruption of the neuromuscular junction precede the clinical phenotype and motor neuron loss in hFUSWT transgenic mice. Hum Mol Genet. 2018;27(3):463&#x2013;74. doi: 10.1093/hmg/ddx415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx415</ArticleId><ArticleId IdType="pmc">PMC5886082</ArticleId><ArticleId IdType="pubmed">29194538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chand KK, Lee KM, Lee JD, Qiu H, Willis EF, Lavidis NA, et al. Defects in synaptic transmission at the neuromuscular junction precedes motor deficits in a TDP-43(Q331K) transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295857</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;68. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, Tsuiji H. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res. 1647;2016:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003651</ArticleId><ArticleId IdType="pubmed">27059391</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan A, Bouffard M, Liao M, Ryan S, Callister JB, Pickering-Brown SM, et al. Expression of C9orf72-related dipeptides impairs motor function in a vertebrate model. Hum Mol Genet. 2018;27(10):1754&#x2013;62. doi: 10.1093/hmg/ddy083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy083</ArticleId><ArticleId IdType="pmc">PMC5932562</ArticleId><ArticleId IdType="pubmed">29528390</ArticleId></ArticleIdList></Reference><Reference><Citation>Maselli RA, Wollman RL, Leung C, Distad B, Palombi S, Richman DP, et al. Neuromuscular transmission in amyotrophic lateral sclerosis. Muscle Nerve. 1993;16(11):1193&#x2013;203. doi: 10.1002/mus.880161109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880161109</ArticleId><ArticleId IdType="pubmed">8105377</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A, Patten SA, Ciura S, Maios C, Therrien M, Drapeau P, et al. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio. PLoS One. 2012;7(7):e42117. doi: 10.1371/journal.pone.0042117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042117</ArticleId><ArticleId IdType="pmc">PMC3407135</ArticleId><ArticleId IdType="pubmed">22848727</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzieciolowska S, Drapeau P, Armstrong GAB. Augmented quantal release of acetylcholine at the vertebrate neuromuscular junction following tdp-43 depletion. PLoS One. 2017;12(5):e0177005. doi: 10.1371/journal.pone.0177005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177005</ArticleId><ArticleId IdType="pmc">PMC5417676</ArticleId><ArticleId IdType="pubmed">28472174</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong GA, Drapeau P. Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. J Neurosci. 2013;33(4):1741&#x2013;52. doi: 10.1523/JNEUROSCI.4003-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4003-12.2013</ArticleId><ArticleId IdType="pmc">PMC6618732</ArticleId><ArticleId IdType="pubmed">23345247</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten SA, Aggad D, Martinez J, Tremblay E, Petrillo J, Armstrong GA, et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight. 2017;2(22).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5752378</ArticleId><ArticleId IdType="pubmed">29202456</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiernagle T. Maintenance of C. elegans. WormBook. 2006:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4781397</ArticleId><ArticleId IdType="pubmed">18050451</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonetta SH, Golombek DA. An automated tracking system for Caenorhabditis elegans locomotor behavior and circadian studies application. J Neurosci Methods. 2007;161(2):273&#x2013;80. doi: 10.1016/j.jneumeth.2006.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2006.11.015</ArticleId><ArticleId IdType="pubmed">17207862</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerfield M. The zebrafish book: a guide for the laboratory use of zebrafish(Danio rerio)1995.</Citation></Reference><Reference><Citation>Buss RR, Drapeau P. Activation of embryonic red and white muscle fibers during fictive swimming in the developing zebrafish. J Neurophysiol. 2002;87(3):1244&#x2013;51. doi: 10.1152/jn.00659.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00659.2001</ArticleId><ArticleId IdType="pubmed">11877498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewamadduma CA, Grierson AJ, Ma TP, Pan L, Moens CB, Ingham PW, et al. Tardbpl splicing rescues motor neuron and axonal development in a mutant tardbp zebrafish. Hum Mol Genet. 2013;22(12):2376&#x2013;86. doi: 10.1093/hmg/ddt082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt082</ArticleId><ArticleId IdType="pmc">PMC3658164</ArticleId><ArticleId IdType="pubmed">23427147</ArticleId></ArticleIdList></Reference><Reference><Citation>Jao L-E, Wente SR, Chen W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc Natl Acad Sci. 2013;110(34):13904&#x2013;9. doi: 10.1073/pnas.1308335110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1308335110</ArticleId><ArticleId IdType="pmc">PMC3752207</ArticleId><ArticleId IdType="pubmed">23918387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan KM, Fujimoto E, Grabher C, Mangum BD, Hardy ME, Campbell DS, et al. The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev Dyn. 2007;236(11):3088&#x2013;99. doi: 10.1002/dvdy.21343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.21343</ArticleId><ArticleId IdType="pubmed">17937395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14(6):1105&#x2013;16. doi: 10.1016/0896-6273(95)90259-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90259-7</ArticleId><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Bercier V, Lissouba A, Liao M, Brustein E, Rouleau GA, et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet. 2011;7(8):e1002214. doi: 10.1371/journal.pgen.1002214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002214</ArticleId><ArticleId IdType="pmc">PMC3150442</ArticleId><ArticleId IdType="pubmed">21829392</ArticleId></ArticleIdList></Reference><Reference><Citation>Brustein E, Saint-Amant L, Buss RR, Chong M, McDearmid JR, Drapeau P. Steps during the development of the zebrafish locomotor network. J Physiol Paris. 2003;97(1):77&#x2013;86. doi: 10.1016/j.jphysparis.2003.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphysparis.2003.10.009</ArticleId><ArticleId IdType="pubmed">14706693</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Amant L, Drapeau P. Time course of the development of motor behaviors in the zebrafish embryo. J Neurobiol. 1998;37(4):622&#x2013;32. doi: 10.1002/(SICI)1097-4695(199812)37:4&lt;622::AID-NEU10&gt;3.0.CO;2-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4695(199812)37:4&lt;622::AID-NEU10&gt;3.0.CO;2-S</ArticleId><ArticleId IdType="pubmed">9858263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo JJ, Schonewille M, Siddique T, Schults AN, Fu R, Bar PR, et al. Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. J Neurophysiol. 2004;91(1):571&#x2013;5. doi: 10.1152/jn.00665.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00665.2003</ArticleId><ArticleId IdType="pubmed">14523070</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin E, Cazenave W, Cattaert D, Branchereau P. Embryonic alteration of motoneuronal morphology induces hyperexcitability in the mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2013;54:116&#x2013;26. doi: 10.1016/j.nbd.2013.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.02.011</ArticleId><ArticleId IdType="pubmed">23466698</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha MC, Pousinha PA, Correia AM, Sebastiao AM, Ribeiro JA. Early changes of neuromuscular transmission in the SOD1(G93A) mice model of ALS start long before motor symptoms onset. PLoS One. 2013;8(9):e73846. doi: 10.1371/journal.pone.0073846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0073846</ArticleId><ArticleId IdType="pmc">PMC3764017</ArticleId><ArticleId IdType="pubmed">24040091</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez G, Tapia JC, Lichtman JW, Fox MA, Sanes JR. Shared resistance to aging and ALS in neuromuscular junctions of specific muscles. PLoS One. 2012;7(4):e34640. doi: 10.1371/journal.pone.0034640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034640</ArticleId><ArticleId IdType="pmc">PMC3317643</ArticleId><ArticleId IdType="pubmed">22485182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119(4):409&#x2013;19. doi: 10.1007/s00401-010-0659-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0659-0</ArticleId><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Drapeau P, Saint-Amant L, Buss RR, Chong M, McDearmid JR, Brustein E. Development of the locomotor network in zebrafish. Prog Neurobiol. 2002;68(2):85&#x2013;111. doi: 10.1016/S0301-0082(02)00075-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0301-0082(02)00075-8</ArticleId><ArticleId IdType="pubmed">12450489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong H, McDearmid JR. Pacemaker and plateau potentials shape output of a developing locomotor network. Curr Biol. 2012;22(24):2285&#x2013;93. doi: 10.1016/j.cub.2012.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2012.10.025</ArticleId><ArticleId IdType="pmc">PMC3525839</ArticleId><ArticleId IdType="pubmed">23142042</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti L, Ghilardi A, Rottoli E, De Maglie M, Prosperi L, Perego C, et al. INaP selective inhibition reverts precocious inter- and motorneurons hyperexcitability in the Sod1-G93R zebrafish ALS model. Sci Rep. 2016;6:24515. doi: 10.1038/srep24515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24515</ArticleId><ArticleId IdType="pmc">PMC4832213</ArticleId><ArticleId IdType="pubmed">27079797</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B, Peuscher MH, Hynynen M, Chen A, Neve RL, Brown RH, Jr, et al. Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Neurosci. 2008;28(43):10864&#x2013;74. doi: 10.1523/JNEUROSCI.1340-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1340-08.2008</ArticleId><ArticleId IdType="pmc">PMC3844745</ArticleId><ArticleId IdType="pubmed">18945894</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieck GC, Prakash YS. Morphological adaptations of neuromuscular junctions depend on fiber type. Can J Appl Physiol. 1997;22(3):197&#x2013;230. doi: 10.1139/h97-014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/h97-014</ArticleId><ArticleId IdType="pubmed">9189302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>